You are invited to meet us at ASH2018, the 60th Annual Meeting of the American Society of Hematology in San Diego, USA. Below we have listed some options for you:
1. Participate in the HARMONY - ELN Breakfast Meeting: 2 December 2018 from 07:25 to 11:00 hrs. in the Manchester Grand Hyatt, Level 4, Coronado DE, 1 Market Place, San Diego, USA.
HARMONY Partners, Associated Members and anyone interested in our Alliance are invited to participate.
To join us, please send an email to the HARMONY Coordination Office.
Download the preliminary program >
Program summary
Speakers
2. Locate us at the exhibition in the booth of the European Hematology Association (EHA) (booth number 2504). EHA is one of the 53 HARMONY Alliance Partners.
Let us know if you would like to make a personal appointment with one of the many HARMONY Alliance representatives who are attending ASH2018 and mail the HARMONY Communication Office.
HARMONY focuses on seven hematologic malignancies: Acute lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkins Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies. Read more about each of the 7 diseases >
ASH2018, the 60th Annual Meeting and Exposition of American Society of Hematology will be attended by hematology professionals from around the world who will gather in Atlanta, Georgia, USA to share, discuss, and learn about the latest information through sessions with thousands of scientific abstracts uncovering every aspect of hematology. ASH2018 is scheduled to be held from 1 to 4 December, 2018 in San Diego, USA, and will focus on the latest advancements, research, and improvement in techniques about hematology and related fields.
Visit the ASH 2018 conference website.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
